322 related articles for article (PubMed ID: 25825013)
1. Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor.
de Luis DA; Diaz Soto G; Izaola O; Romero E
J Diabetes Complications; 2015; 29(4):595-8. PubMed ID: 25825013
[TBL] [Abstract][Full Text] [Related]
2. Role of genetic variation in the cannabinoid receptor gene (CNR1) (G1359A polymorphism) on weight loss and cardiovascular risk factors after liraglutide treatment in obese patients with diabetes mellitus type 2.
de Luis DA; Ovalle HF; Soto GD; Izaola O; de la Fuente B; Romero E
J Investig Med; 2014 Feb; 62(2):324-7. PubMed ID: 24322329
[TBL] [Abstract][Full Text] [Related]
3. Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes.
Mensberg P; Nyby S; Jørgensen PG; Storgaard H; Jensen MT; Sivertsen J; Holst JJ; Kiens B; Richter EA; Knop FK; Vilsbøll T
Diabetes Obes Metab; 2017 Feb; 19(2):172-180. PubMed ID: 27717126
[TBL] [Abstract][Full Text] [Related]
4. Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study.
Chedid V; Vijayvargiya P; Carlson P; Van Malderen K; Acosta A; Zinsmeister A; Camilleri M
Neurogastroenterol Motil; 2018 Jul; 30(7):e13313. PubMed ID: 29488276
[TBL] [Abstract][Full Text] [Related]
5. Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial.
Tanaka K; Saisho Y; Manesso E; Tanaka M; Meguro S; Irie J; Sugiura H; Kawai T; Jinzaki M; Cobelli C; Itoh H;
Clin Drug Investig; 2015 Oct; 35(10):675-84. PubMed ID: 26369653
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-Like Peptide 1 (GLP-1) Receptor Variants and Glycemic Response to Liraglutide: A Pharmacogenetics Study in Iranian People with Type 2 Diabetes Mellitus.
Eghbali M; Alaei-Shahmiri F; Hashemi-Madani N; Emami Z; Mostafavi L; Malek M; Khamseh ME
Adv Ther; 2024 Feb; 41(2):826-836. PubMed ID: 38172377
[TBL] [Abstract][Full Text] [Related]
7. Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study.
Jensterle M; Pirš B; Goričar K; Dolžan V; Janež A
Eur J Clin Pharmacol; 2015 Jul; 71(7):817-24. PubMed ID: 25991051
[TBL] [Abstract][Full Text] [Related]
8. Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes.
Santilli F; Simeone PG; Guagnano MT; Leo M; Maccarone MT; Di Castelnuovo A; Sborgia C; Bonadonna RC; Angelucci E; Federico V; Cianfarani S; Manzoli L; Davì G; Tartaro A; Consoli A
Diabetes Care; 2017 Nov; 40(11):1556-1564. PubMed ID: 28912305
[TBL] [Abstract][Full Text] [Related]
9. Liraglutide vs. lixisenatide in obese type 2 diabetes mellitus patients: What effect should we expect in routine clinical practice?
Moreno-Fernandez J; Garcia-Seco JA; Seco Segura AM; Garcia-Seco F; Rozas Moreno PJ; Aguirre Sanchez-Covisa M
Prim Care Diabetes; 2020 Feb; 14(1):68-74. PubMed ID: 31171461
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial.
Garvey WT; Birkenfeld AL; Dicker D; Mingrone G; Pedersen SD; Satylganova A; Skovgaard D; Sugimoto D; Jensen C; Mosenzon O
Diabetes Care; 2020 May; 43(5):1085-1093. PubMed ID: 32139381
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
[TBL] [Abstract][Full Text] [Related]
12. Exposure-response analyses of liraglutide 3.0 mg for weight management.
Wilding JP; Overgaard RV; Jacobsen LV; Jensen CB; le Roux CW
Diabetes Obes Metab; 2016 May; 18(5):491-9. PubMed ID: 26833744
[TBL] [Abstract][Full Text] [Related]
13. Effects of a high-protein/low-carbohydrate versus a standard hypocaloric diet on adipocytokine levels and cardiovascular risk factors during 9 months, role of rs6923761 gene variant of glucagon-like peptide 1 receptor.
de Luis DA; Aller R; Izaola O; Romero E
J Endocrinol Invest; 2015 Nov; 38(11):1183-9. PubMed ID: 26015316
[TBL] [Abstract][Full Text] [Related]
14. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
[TBL] [Abstract][Full Text] [Related]
15. Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study.
Perna S; Guido D; Bologna C; Solerte SB; Guerriero F; Isu A; Rondanelli M
Aging Clin Exp Res; 2016 Dec; 28(6):1251-1257. PubMed ID: 26749118
[TBL] [Abstract][Full Text] [Related]
16. Effect of rs6923761 gene variant of glucagon-like peptide 1 receptor on metabolic response and weight loss after a 3-month intervention with a hypocaloric diet.
de Luis DA; Aller R; Izaola O; Lopez JJ; Gomez E; Torres B; Soto GD
J Endocrinol Invest; 2014 Oct; 37(10):935-9. PubMed ID: 24972699
[TBL] [Abstract][Full Text] [Related]
17. One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target.
Rosenstock J; Rodbard HW; Bain SC; D'Alessio D; Seufert J; Thomsen AB; Svendsen CB; DeVries JH;
J Diabetes Complications; 2013; 27(5):492-500. PubMed ID: 23746555
[TBL] [Abstract][Full Text] [Related]
18. Role of rs6923761 gene variant in glucagon-like peptide 1 receptor in basal GLP-1 levels, cardiovascular risk factor and serum adipokine levels in naïve type 2 diabetic patients.
de Luis DA; Aller R; Izaola O; Bachiller R
J Endocrinol Invest; 2015 Feb; 38(2):143-7. PubMed ID: 25200998
[TBL] [Abstract][Full Text] [Related]
19. Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled study.
Elkind-Hirsch KE; Shaler D; Harris R
J Diabetes Complications; 2020 Apr; 34(4):107548. PubMed ID: 32046931
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study.
Díaz-Soto G; de Luis DA; Conde-Vicente R; Izaola-Jauregui O; Ramos C; Romero E
Diabetes Res Clin Pract; 2014 Apr; 104(1):92-6. PubMed ID: 24530118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
